Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVINASDAQ:CELZNASDAQ:CINGNASDAQ:ME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.09+5.8%$1.01$0.62▼$7.50$20.24M0.771.84 million shs188,318 shsCELZCreative Medical Technology$2.50+11.6%$2.08$1.69▼$6.90$6.46M1.9855,058 shs265,188 shsCINGCingulate$4.45$4.12$1.80▼$20.83$18.89M-0.851.10 million shs147,636 shsME23andMe$0.50-35.3%$0.50$0.53▼$10.81$13.36M1.191.41 million shs29.28 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie0.00%-8.40%+4.81%-2.68%+142.87%CELZCreative Medical Technology0.00%+13.64%+25.00%-13.19%-32.98%CINGCingulate0.00%+1.14%+22.93%+12.37%+680.70%ME23andMe0.00%0.00%0.00%-72.18%-93.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie2.2178 of 5 stars3.83.00.00.00.00.00.6CELZCreative Medical Technology0.3008 of 5 stars0.03.00.00.00.00.01.3CINGCingulate2.1566 of 5 stars3.52.00.00.02.50.80.6ME23andMeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 3.50Strong Buy$3.00175.23% UpsideCELZCreative Medical Technology 0.00N/AN/AN/ACINGCingulate 3.00Buy$26.00484.27% UpsideME23andMe 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CELZ, CING, ME, and BIVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.005/19/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $11.004/21/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.003/22/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$2.54 per shareN/ACELZCreative Medical Technology$10K647.50N/AN/A$3.63 per share0.69CINGCingulateN/AN/AN/AN/A$2.32 per shareN/AME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$32.12M-$7.91N/A∞N/AN/A-100.88%-78.49%8/21/2025 (Estimated)CELZCreative Medical Technology-$5.49M-$3.81N/AN/AN/AN/A-85.26%-81.49%8/8/2025 (Estimated)CINGCingulate-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ALatest CELZ, CING, ME, and BIVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q3 2025BIVIBioVie-$0.32-$0.15+$0.17-$0.15N/AN/A5/9/2025Q1 2025CELZCreative Medical Technology-$0.52-$0.83-$0.31-$0.83N/A$0.00 million5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/ACELZCreative Medical TechnologyN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A9.319.31CELZCreative Medical TechnologyN/A27.4327.42CINGCingulate0.161.871.87ME23andMeN/A1.050.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%CELZCreative Medical Technology1.42%CINGCingulate41.31%ME23andMe36.10%Insider OwnershipCompanyInsider OwnershipBIVIBioVie2.39%CELZCreative Medical Technology2.80%CINGCingulate5.27%ME23andMe26.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie1018.57 million18.13 millionNo DataCELZCreative Medical Technology52.59 million2.51 millionNot OptionableCINGCingulate204.25 million4.02 millionNot OptionableME23andMe77026.83 million19.77 millionNot OptionableCELZ, CING, ME, and BIVI HeadlinesRecent News About These CompaniesICO Imposes 2.31 Million Pound Fine on 23andMeJune 19 at 1:10 PM | govinfosecurity.com23andMe Could Owe You Up to $10,000 After Its Data Breach SettlementJune 19 at 1:10 PM | cnet.com23andMe Bankruptcy Judge Rejects Texas Effort to Halt Data SaleJune 18 at 10:08 PM | news.bloomberglaw.comBattle for 23andMe (and its data) growsJune 18 at 5:06 PM | finance.yahoo.comGene data: British data protection fine for 23andmeJune 18 at 6:14 AM | heise.deOklahoma files federal lawsuit against 23andMeJune 17 at 8:12 PM | kgou.org23andMe fined millions by watchdog after ‘profoundly damaging’ cyber attack exposing genetic dataJune 17 at 8:12 PM | lbc.co.ukUK Watchdogs Fine 23andMe $3.1M for Data Security ViolationsJune 17 at 8:12 PM | msn.comAnne Wojcicki on genetic privacy, data security and the money behind her bid for 23andMeJune 17 at 3:11 PM | bizjournals.com23andMe co-founder wins bid to take back control of companyJune 17 at 3:11 PM | massdevice.comICO fines bankrupt 23andMe £2.3m for massive privacy breachJune 17 at 3:11 PM | sharecast.comAnne Wojcicki wins bid to buy back 23andMe for $305MJune 17 at 3:11 PM | medtechdive.comUK regulator fines 23andMe over massive genetic data breachJune 17 at 3:11 PM | biometricupdate.com23andMe co-founder Anne Wojcicki regains control of bankrupt genetic testing companyJune 17 at 10:10 AM | msn.com23andMe's Co-Founder to Buy Company; Makes Privacy PledgeJune 17 at 10:10 AM | govinfosecurity.com23andMe fined £2.31m over UK users' genetic data breachJune 17 at 10:10 AM | pharmaphorum.comAnne Wojcicki's bid to buy back 23andMe may not end a legal fight over DNA customer dataJune 17 at 10:10 AM | aol.comUK watchdog fines 23andMe over 2023 data breachJune 17 at 10:10 AM | finance.yahoo.comUK ICO Fines 23andMe £2.3m for Data Protection FailingsJune 17 at 10:10 AM | infosecurity-magazine.com23andMe Fined £2.31 Million by UK Over Genetic Data LeakJune 17 at 10:10 AM | bloomberg.comOne Tech Tip: How to protect your 23andMe genetic dataJune 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyAmong the Market’s Most Shorted: 2 Firms With +40% Short InterestBy Leo Miller | June 3, 2025View Among the Market’s Most Shorted: 2 Firms With +40% Short InterestCELZ, CING, ME, and BIVI Company DescriptionsBioVie NASDAQ:BIVI$1.09 +0.06 (+5.83%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.13 +0.04 (+3.58%) As of 06/18/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Creative Medical Technology NASDAQ:CELZ$2.50 +0.26 (+11.61%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.55 +0.05 (+1.96%) As of 06/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Cingulate NASDAQ:CING$4.45 0.00 (0.00%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$4.60 +0.15 (+3.26%) As of 06/18/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
